enzh-TWfrdeitjaptrues

Jorge Castillo MD, and Sandra Kanan NPOctober, 2013: Dear Patients, Caregivers, and Friends of the Bing Center for WM: It gives me great pleasure to introduce to you two outstanding individuals who recently joined the Bing Center for Waldenstrom’s Macroglobulinemia at the Dana Farber Cancer Institute. Many of you have had the opportunity to meet Sandra Kanan, NP and Jorge Castillo, MD, during your recent clinic visits, and I wanted to take the opportunity to formally introduce you to these bright, talented, and dedicated practitioners who will soon be leading the Waldenstrom’s clinical effort for our center. Both individuals were recruited to our center, after national searches, in an effort to increase our capacity to care for a rapidly growing patient population. Over 1,000 patients with WM are expected to be seen this year, with representation from all over the globe. The increased visitations have been prompted by the discovery of the mutation in the MYD88 gene in WM which was discovered by the dedicated laboratory researchers of our center and reported in the New England Journal of Medicine last year. The discovery of the MYD88 mutation prompted research efforts that now have unveiled new opportunities for targeted therapy of WM, including the use of ibrutinib, an inhibitor of Bruton’s Tyrosine Kinase (BTK) which is activated by the MYD88 mutation.

A large clinical trial undertaken by the Bing Center with our colleagues at Stanford University and Memorial Sloan-Kettering Cancer Center showed that ibrutinib was highly active in patients with relapsed or refractory WM. These revelations led to a “breakthough” Fast Track status by the U.S. Food and Drug Administration for the approval of ibrutinib in WM, the first time this status had ever been conveyed, thus permitting accelerated approval for this drug for WM. These advances have also led to the identification of new drug targets in the MYD88 pathway, and the development of new agents in collaboration with our colleagues at Harvard Medical School. To help facilitate these efforts, Dr. Steve Treon will be transitioning from the clinic to spearhead new drug development efforts made possible through the generous support of many individuals and the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). Dr. Castillo and NP Kanan will assume care of patients in our WM clinic starting this December, with Dr. Treon and our clinic staff and clinical trials group in support of their efforts. This will include discussion of all clinic cases for the foreseeable future at our weekly WM rounds. Dr. Castillo will also be developing new clinical trials for WM, and indeed several “Letters of Intent” have recently been submitted by him for the investigation of several new drugs for WM.

Sandra Kanan, NP, holds a Bachelor of Science degree in Biology from Seattle University and a Master’s of Science degree in Nursing from the Pacific Lutheran University. Prior to joining the Bing Center for WM, Sandra worked for several years as a nurse practitioner at the Arizona Cancer Center inpatient adult hematology/oncology and bone marrow transplant units, and at a community oncology practice in Washington State. She was an oncology and infusion nurse in both the inpatient and outpatient settings at these positions which gave her immense knowledge about the care of patients effected by plasma cell malignancies. In April 2013, NP Kanan was recruited to the Bing Center. She was mentored by Patricia Sheehy-Severns, NP who left the Bing Center after many years of dedicated service to care for her young son. NP Kanan can be reached through the Bing Center main line at 617.632.2681 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr Jorge J. Castillo comes to us from the W. Alpert Medical School of Brown University where he served as a faculty member spending dividing his time between clinical care of lymphoma and leukemia patients, clinical research into lymphomatous diseases, and teaching residents and medical students. He focused his clinical research on identifying risk factors associated with the development of hematological malignancies. His achievements included a series of investigator-initiated prospective clinical trials using non-chemotherapeutic regimens, which prompted multi-institutional studies of rare lymphomas such as plasmablastic lymphoma and HIV-associated T-cell lymphomas. He is a prolific writer, who has authored 60 manuscripts that have been published in highly prestigious medical journals. Dr Castillo can also be contacted through the Bing Center main line at 617.632.2681 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it..

In closing, I would like to thank all our patients, caregivers and friends for your support of the Bing Center for WM. These are exciting times for all of us who have been involved in the care of WM patients and research. The genomic revelations made possible through the whole genome project, and the identification of new targets and drugs that came with these revelations have placed us on a direct path to finding a cure for this disease. Your help and ongoing support will get us there soon. I thank you for being there for us, and for your welcome of our new staff members who will help us in our efforts to triumph over WM. As always, please feel free to contact me with any questions and concerns at 617 632 6285, or at This email address is being protected from spambots. You need JavaScript enabled to view it..

Sincerely,

Christopher J. Patterson
Administrative Director
Bing Center for Waldenstrom’s Macroglobulinemia
Dana Farber Cancer Institute

Latest Bing Center News

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.

Read more..

COVID-19 Information for Our Patients

COVID-19 Information for Our Patients

The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.

Read more..

Waldenström Macroglobulinemia Specialty Channel

Waldenström Macroglobulinemia Specialty Channel

Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.

Read more..

Dana-Farber to Test Blood Cancer Drug in COVID-19

Dana-Farber to Test Blood Cancer Drug in COVID-19

Scientists at Dana-Farber have launched a clinical test of a blood-cancer drug in patients that have the COVID-19 virus. The test follows several case reports in which the drug, ibrutinib, appeared to protect against lung damage and respiratory distress caused by the novel virus.

Read more..

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™

Read more..

Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

We are excited to announce this new webcast on diagnosis, risk stratification, and current and emerging therapies for Waldenström's Macroglobulinemia (WM).

Read more..

Watch Dr. Jorge Castillo’s engaging “Ask the Doctor” session

Watch Dr. Jorge Castillo’s engaging “Ask the Doctor” session

Fifty WMers from the Philly WM Support Group enjoyed a lively, engaging and informative conversation with Dr. Jorge Castillo, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute.

Read more..

Drs. Castillo and Kastritis have joined the IWMF Scientific Advisory Committee

Drs. Castillo and Kastritis have joined the IWMF Scientific Advisory Committee

The IWMF is proud to welcome two new members to its Scientific Advisory Committee (SAC) chaired by Dr. Steven Ansell of the Mayo Clinic and Dr. Stephen Treon of the Dana-Farber Cancer Institute. The new members, Dr. Jorge Castillo from Dana-Farber, Boston, USA, and Dr. Efstathios Kastritis of Athens, Greece, were invited to participate because of their expertise in specific research areas identified by the IWMF-LLS Strategic Research Roadmap for WM.

Read more..

Waldenstrom's Song - Tim Salz, UC Berkeley, CA

Waldenstrom's Song - Tim Salz, UC Berkeley, CA

This is a song I wrote for all of my fellow Wallies out there. Thanks for watching.

Read more..

Robert J. Manning, FM, RNG

Robert J. Manning, FM, RNG

I first met Bob Manning in early 2004 when I started volunteering at the Bing Center. My boss introduced me to Bob, and said 3 words, "Help this guy". The first thing I noticed was Bob's badge, which contained his name, followed by the credentials, FM, RNG. Bob told me they meant, "Former Marine, Real Nice Guy". That's when I knew this wasn't going to be a boring relationship.

Read more..